Inogen, Inc (INGN) Sets New 52-Week High at $98.78
Inogen, Inc (NASDAQ:INGN) hit a new 52-week high during trading on Wednesday . The company traded as high as $98.78 and last traded at $98.78, with a volume of 101,440 shares trading hands. The stock had previously closed at $97.33.
A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Needham & Company LLC increased their price objective on shares of Inogen from $96.00 to $108.00 and gave the company a “strong-buy” rating in a research note on Friday, June 9th. BidaskClub raised shares of Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 8th. Stifel Nicolaus increased their price objective on shares of Inogen from $65.00 to $75.00 and gave the company a “hold” rating in a research note on Wednesday, May 10th. Finally, J P Morgan Chase & Co increased their price objective on shares of Inogen to $102.00 and gave the company an “overweight” rating in a research note on Monday, June 26th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $91.60.
The company’s 50 day moving average price is $94.39 and its 200 day moving average price is $85.84. The firm has a market cap of $2.04 billion, a PE ratio of 85.40 and a beta of 1.02.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.10. The company had revenue of $64.10 million for the quarter, compared to analyst estimates of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. Inogen’s revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.25 earnings per share. Equities analysts anticipate that Inogen, Inc will post $1.21 earnings per share for the current year.
In related news, Director Raymond Huggenberger sold 15,300 shares of Inogen stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $90.88, for a total value of $1,390,464.00. Following the sale, the director now owns 7,808 shares of the company’s stock, valued at approximately $709,591.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $92.45, for a total value of $231,125.00. Following the completion of the sale, the executive vice president now directly owns 6,964 shares in the company, valued at approximately $643,821.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 57,467 shares of company stock worth $5,288,415. 5.31% of the stock is currently owned by insiders.
A number of institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in Inogen in the 2nd quarter valued at approximately $442,000. Koch Industries Inc. raised its position in Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after buying an additional 653,747 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Inogen in the 2nd quarter valued at approximately $280,000. Piedmont Investment Advisors LLC acquired a new stake in Inogen in the 2nd quarter valued at approximately $336,000. Finally, Ameritas Investment Partners Inc. raised its position in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares during the last quarter.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.